The comparison of prognoses between radiotherapy and radical prostatectomy in patients with high risk localised or locally advanced prostate cancer treated with neoadjuvant hormonal therapy

There is general consensus that single modality therapy is insufficient for high risk prostate cancer. As such, there are already numerous trials ongoing that are addressing the role of multimodal therapy, including multimodal neoadjuvant therapy. Therefore, this question of surgery vs. EBRT alone may be a moot point.